Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer

CASTRES, France, June 21, 2024 /PRNewswire/ — Pierre Fabre Laboratories has been awarded the “Prix Galien International” Prize in the “Best Product for a Rare/Orphan Disease” category for EBVALLO® (tabelecleucel), indicated as monotherapy for the treatment of patients with…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.